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http://dx.doi.org/10.1016/j.kjms.201Abstract The incidence of upper tract urothelial cancer (UTUC) has gradually increased over
the past 30 years. Although most reports have shown that UTUC occurs more frequently in men
than in women, women have been found to have a worse prognosis than men. In Taiwan, a high
incidence of UTUC has been reported, with an unusual minor predominance of female cases.
The purpose of this study was to determine the influence of gender on the outcome of patients
with UTUC after nephroureterectomy and bladder cuff excision. From January 1990 to
December 2007, 301 patients diagnosed with UTUC were admitted at our institution. A retro-
spective analysis of the effect of gender on the clinical outcome was performed. We compared
the 5-year bladder recurrence-free, progression-free, and disease-specific survival rates.
While we did not observe any differences between men and women in bladder recurrence-
free, progression-free, or disease-specific survival rates, we found that female patients had
a significantly higher percentage of contralateral recurrence than the males (5.9% vs. 0.8%,
p Z 0.019).
Copyright ª 2012, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights
reserved.of Urology, Kaohsiung Medical University Hospital, No. 100, Tzyou 1st Road, Kaohsiung 807, Taiwan.
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Upper tract urothelial cancer (UTUC), including renal pelvis
and ureter diseases, is a rare disease, representing only 5%
of all urothelial cancers (UCs). In developed countries, UC is
a common malignancy in men. However, it is less common
in women in most regions of the world, especially in
Southern European countries; for example, a male-to-
female ratio of 7:1 for UC incidence has been reported in
Spain [1e3].
Although bladder cancer is less common in women, they
have been reported to have a worse prognosis than men.
Mungan et al. demonstrated that this difference in prog-
nosis is not entirely explained by the fact that a higher
proportion of this disease is at an advanced stage at the
time of diagnosis in women [4,5]. In Taiwan, a high inci-
dence of UTUC has been reported, with an unusual minor
predominance of female cases [6].
Nephroureterectomy with bladder cuff excision (radical
nephroureterectomy) remains the standard therapy for
UTUC [7]. However, even after undergoing this surgery,
tumor recurrence is still common. Patients may develop the
signs and symptoms of recurrence in the urinary bladder,
local retroperitoneal space, or contralateral upper urinary
tract (UT) [8]. To date, the definite risk factors for disease
recurrence and patient survival after radical nephrour-
eterectomy have not been elucidated. The purpose of this
study was to investigate whether there are gender-related
prognostic factors associated with UTUC.
Materials and methods
From January 1990 to December 2007, 414 patients were
diagnosed with UTUC and underwent radical nephrour-
eterectomy at our institution. Among the 414 patients, 113
were excluded from this studyd59 had previous or
concomitant urinary bladder tumors, 23 had lymph node or
distant metastasis at the time of diagnosis, 5 had bilateral
synchronous UTUC, and 26 provided incomplete data. The
remaining 301 patients, who received radical nephrour-
eterectomy for primary UTUC, were included in this study.
The study was approved by the Institutional Review Board.
The clinicopathological data were recorded retrospec-
tively. The tumors were staged according to the 2002
American Joint Committee on Cancer classification and
were graded according to the 1998 World Health Organi-
zation classification. Postoperative follow-up involved
recording of interval history, physical examination, urinal-
ysis, urine cytology, radiography of the chest, abdominal
ultrasonography, excretory urography, and computed
tomography of the abdomen. Cystoscopy was performed at
intervals of 3 months for the first 2 years, 6 months for the
next 2 years, and annually thereafter. Excretory urography
or computed tomography was performed annually during
follow-up or when clinically indicated. The treatment
method and follow-up policy were completely the same for
both men and women.
The predictive value of the clinicopathological prog-
nostic factors was analyzed with respect to disease-specific
or recurrence-free survival rates. Recurrence-free survival
was calculated as the time interval between the date ofnephroureterectomy and the date of first documented
clinical recurrence. Disease progression was defined as
local retroperitoneal space, contralateral upper UT, and
distant-organ metastasis. Disease-specific survival was
defined as the time interval between the date of neph-
roureterectomy and the end point, including death or
censoring. Bladder recurrence was included only in disease
recurrence but not in disease progression. Progression-free
survival was defined as the time interval between the date
of nephroureterectomy and the observation of disease
progression. Categorical data were analyzed using Pearson
Chi-square or Fisher exact test. Univariate and multivariate
analyses were performed using the KaplaneMeier method,
using the log rank test and Cox proportional hazards
regression model. A p value <0.05 was considered to be
statistically significant. Statistical analyses were performed
using SPSS version 17.0 (SPSS Inc., Chicago, IL, USA).Results
In this study, we observed 131 men and 170 women whose
median age was 66 years (range: 23e87 years), with
a median follow-up time of 33 months (range: 1e196
months). The clinical characteristics of these patients are
summarized in Table 1. The overall male-to-female ratio
was 1:1.3. Tumor arising from the renal pelvis or calyx
was found in 105 patients (34.9%), tumor from the ureter in
142 patients (47.2%), and tumor from both areas in 54 cases
(17.9%). In the 301 patients studied, pathological stages
were distributed as follows: 36 (12%) patients had pTa/pTis
tumors, 86 (28.5%) had pT1 tumors, 88 (29.2%) had pT2
tumors, 77 (25.6%) had pT3 tumors, and 14 (4.7%) had
pT4 tumors. In total, 122 patients (40.5%) had nonmuscle-
invasive tumors, while 179 (59.5%) had muscle-invasive
tumors; 130 tumors (43.2%) were low grade, and 171
(56.8%) were high grade.
Segregating the study population according to gender
revealed that the female patients were not older than the
male ones at the time of performing the surgery. The
percentage of female smokers was significantly lower than
that of male smokers (12.9% vs. 40.5%, p < 0.001). There
was no significant difference between male and female
patients in other variables, such as gross hematuria, tumor
side (right, left), tumor location (calyx, pelvis, ureter),
multiplicity, type of nephroureterectomy (open, laparo-
scopic), type of bladder cuff excision (transurethral inci-
sion, open), tumor stage (Ta/Tis/T1, T2, T3, T4), and grade
(low, high). Compared with men, women had similar
proportions of high-grade, high-stage, and multiple tumors.
In the overall oncologic outcomes of patients with UTUC,
women had a significantly higher rate of contralateral
recurrence than men (5.9% vs. 0.8%, p Z 0.019). This
difference could not be explained by the difference of
adherence to medication. There was no statistically
significant difference between men and women with regard
to percentage of bladder recurrence, local recurrence,
distant metastasis, disease progression, and death from
disease-related causes. The bladder recurrence-free
survival was not different between men and women
(pZ 0.137), Progression-free and disease-specific survivals
were significantly associated with tumor stage (both
Table 1 Characteristics of 301 patients with upper tract urothelial cancer.
Variables Total (n Z 301) Male (n Z 131) Female (n Z 170) p
Age 0.924
65 141 (46.8%) 54 (41.2%) 71 (41.8%)
>65 160 (53.2%) 77 (58.8%) 99 (58.2%)
Smoking <0.001
Yes 75 (24.9%) 53 (40.5%) 22 (12.9%)
No 226 (75.1%) 78 (59.5%) 148 (87.1%)
Gross hematuria 0.658
Yes 233 (77.4%) 103 (78.6%) 130 (76.5%)
No 68 (22.6%) 28 (21.4%) 40 (23.5%)
Tumor side 0.355
Right 147 (48.8%) 60 (45.8%) 87 (51.2%)
Left 154 (51.2%) 71 (54.2%) 83 (48.8%)
Tumor location 0.849
Renal pelvis or calyx 105 (34.9%) 45 (34.4%) 60 (35.3%)
Ureter 142 (47.2%) 64 (48.9%) 78 (45.9%)
Multiple 54 (17.9%) 22 (16.8%) 32 (18.8%)
Type of NU 0.778
Open 246 (81.7%) 108 (82.4%) 138 (81.2%)
Laparoscopy 55 (18.3%) 23 (17.6%) 32 (18.8%)
Type of BCE 0.244
Open 210 (69.8%) 96 (73.3%) 114 (67.1%)
Transurethral incision 91 (30.2%) 35 (26.7%) 56 (32.9%)
pT stage 0.331
Ta/Tis 36 (12.0%) 10 (7.6%) 26 (15.3%)
T1 86 (28.5%) 37 (28.2%) 49 (28.8%)
T2 88 (29.2%) 42 (32.1%) 46 (27.1%)
T3 77 (25.6%) 36 (27.5%) 41 (24.1%)
T4 14 (4.7%) 6 (4.6%) 8 (4.7%)
Tumor grade 0.082
Low 130 (43.2%) 64 (48.9%) 66 (38.8%)
High 171 (56.8%) 67 (51.1%) 104 (61.2%)
Data are presented as n (%).
Abbreviations: BCE Z bladder cuff excision; NU Z nephroureterectomy.
The role of gender in upper tract urothelial cancer 39p < 0.001) and tumor grade (p Z 0.006 and p Z 0.002,
respectively). In a multivariate analysis after adjusting for
tumor stage and tumor grade, gender did not significantly
affect progression-free and disease-specific survivals
(p Z 0.297 and p Z 0.679, respectively). Five-year
progression-free survival rates of men and women were
81.3% and 79.5%, respectively (p Z 0.371, Fig. 1A). Five-
year cancer-specific survival rates of men and women
were 81.5% and 86.7%, respectively (p Z 0.450, Fig. 1B).Discussion
The standard procedure for treating UTUC is nephrour-
eterectomy with bladder cuff excision. However, UC
sometimes recurs after standard surgery in the bladder,
either in the previous surgical area or in the contralateral
upper UT. Previous studies demonstrated that 25e69% ofthe patients who underwent nephroureterectomy for UTUC
had subsequent bladder tumor recurrence [9,10]. Recur-
rence in the local retroperitoneal space is rare; several
studies reported a 3e9% local recurrence [11,12]. Similarly,
contralateral UT recurrence rates are low, ranging from
3.1% to 11.3% [13]. Several factors, including patient age,
tumor size, tumor location, history of bladder UC, tumor
multifocality, tumor grade, and tumor stage, are well-
known risk factors for cancer-specific survival of patients
with UTUC [14]. However, in most studies, gender was not
considered as a variable in prognostic analyses.
The importance of gender in the development and
prognosis of UC is currently unknown. A majority of reports
in the current literature suggest that UTUC is about three
times more common in men than in women in countries
other than Taiwan [15]. Excessive exposure to cigarette
smoke and industrial chemicals in men have been suggested
to have a causative role [16]. In bladder UC, Mungan et al.
Figure 1. KaplaneMeier survival analysis showing (A) progression-free survival and (B) disease-specific survival in patients of
upper tract urothelial carcinoma treated with nephroureterectomy.
40 Y.-H. Chou et al.showed that female patients had poorer outcomes than
males, even after adjusting for tumor stage [4]. Among
patients with UTUC, Lughezzani et al. reported that women
undergoing nephroureterectomy had a higher proportion of
pT3 UTUC, and a higher proportion of grade III/IV UTUC,
with respect to men. After accounting for other causes of
mortality, cancer-specific mortality rates were higher in
women than in men. However, in multivariate competing
risks regression models, no statistically significant differ-
ence in survival was recorded between men and women
[17e19]. Another study reported that women neither had
more advanced tumor stage at nephroureterectomy nor had
demonstrated worse survival than men [20]. The fact that
male UTUC patients have a better prognosis than female
patients with the same disease may be explained by
inequalities in health care between men and women and
inferior quality of care for women, for example, because of
reduced inpatient length of stay and disparities in referral
patterns for hematuria [21].
The impact of gender on the prognosis of UTUC is
unknown. There are no evidence-based recommendations
to guide health-care professionals. Moreover, in Taiwan,
UTUC presents with two unusual characteristics: the first
being the high incidence of urinary upper tract compared
with lower tract cancers and the second is the prevalence
of UTUC among women, which is higher than anywhere else
in the world. In fact, the incidence of UTUC is slightly
higher in Taiwanese women than in men, as we first re-
ported in 1999 [6].
The Taiwan Cancer Registry published that, from 1995 to
2003, the incidence of UTUC ranged from 3.37 to 4.62 per
100,000 women (ICD-9 189.1 and 189.2). During those
9 years, there were 3178 female and 2970 male patients,
with a female-to-male ratio of 1.07, demonstrating a slight
female predominance. This study emphasizes the prognosis
of UTUC within the Taiwanese population. Our study
demonstrates that women had a significantly higher
percentage of contralateral recurrence than men. There
were no significant differences between men and women in
the percentage of bladder recurrence, local recurrence,
distant metastasis, disease progression, or deaths from
disease-related causes. Our results thus show that the
female gender is not a harmful factor with regard to
survival, but is a risk factor for contralateral recurrence.This finding of gender-related contralateral recurrence of
UTUC has clinical implications. Besides cystoscopy, exami-
nation of the upper UT by renal ultrasonography and
intravenous or retrograde pyelography should be performed
during follow-up of female patients after an initial
nephroureterectomy.
There is no uniform theory to explain the differential
incidence, severity, and prognosis of UTUC between
genders. Differences between genders in carcinogenic
exposures, routes of entry, or enzymatic processing of
environmental substances may account for the clinical
discrepancies. Excessive environmental exposure to
carcinogens, such as tobacco and industrial chemicals, in
men has been suggested to play a role. However, a previous
study showed that the gender-related differential risk of
developing bladder UC persisted even after controlling
these factors [12]. Little effort has been spent exploring
other environmental factors or biological pathways that
could underlie the heterogeneity between genders.
Another possible explanation for the differential behavior
of UC between genders has been postulated to be a rela-
tionship with sex steroids and their receptors [22e25].
Because UC is more common in men than in women,
androgen or androgen receptors may be one of the etio-
logical factors for the development of UC. Consequently,
estrogen or antiandrogen steroids may act as protective
factors. Experimental studies have demonstrated that
androgens either promote or do not inhibit the growth of
UC, and that estrogens have the opposite effect [26].
Female patients, therefore, may theoretically be expected
to have better outcomes than males as a result of the
protective effect of estrogens or antiandrogens. In patients
with UTUC, establishing a link between hormone status and
clinical outcomes would require additional basic mecha-
nistic and clinical studies.
Tobacco consumption is an important risk factor for UC.
However, in Taiwan, most smokers are men, and very few
women smoke: among people aged 60e69 years, the rates
of current smoking in men and women are 40.9% and 3.2%,
respectively [27]. This suggests that although cigarette
smoking has been repeatedly shown to confer a significant
risk of bladder UC, smoking is not a major risk factor for
women in Taiwan. Female patients may thus develop UC as
a result of other etiological factors.
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nance in our study may be difference in exposure to
carcinogen. Environmental carcinogens, other than tobacco
smoke, might explain the high incidence of UTUC in Taiwan.
First, people living in blackfoot disease areas of southern
Taiwan have a higher risk of UC because of arsenic intoxi-
cation from water [28]. Second, many people regularly
consume herbal medicines in Taiwan. Some studies have
reported a high prevalence of UC in patients with Chinese
herb nephropathy, which is associated with the use of
carcinogenic remedies containing aristolochic acid [29,30].
Aristolochic acidemediated UC is characterized by renal
failure and UTUC, and has an unusual female predomi-
nance. Other, yet unidentified factors may contribute to
the unusual presentation of female patients with UTUC in
Taiwan. Further studies are needed to explore whether
aristolochic acid or other compounds in herbal preparations
or folk food remedies are responsible for the development
of end-stage renal disease and UTUC. We believe that the
etiology of UTUC in Taiwanese female patients is different
from that of UC in other countries. Differences in the
pathogenesis of the development may also result in
a different clinical course of UTUC.
This study has several limitations. The data were
collected retrospectively, and the study is therefore prone
to all the biases of a retrospective report. In addition, the
results are limited to experience in Taiwan, an area with an
unusually high prevalence of women with UTUC. Moreover,
although this study included a relatively large case series, it
may not have been statistically powerful enough to detect
small differences in survival and tumor recurrence in rela-
tion to some variables such as renal function and arsenic
exposure. Despite these limitations, the results of this
relatively large cohort study provide a better understanding
of the role of gender in the prognosis of UTUC in patients
treated with radical nephroureterectomy and bladder cuff
excision.
In conclusion, a high incidence of UTUC has been re-
ported in Taiwan, with an unexpected female predomi-
nance. Women had a significantly higher rate of
contralateral recurrence than men. Female patients did not
have worse outcomes than males after long-term follow-up.
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